# Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

> **NCT01486446** · PHASE1,PHASE2 · COMPLETED · sponsor: **Xenon Pharmaceuticals Inc.** · enrollment: 8 (actual)

## Conditions studied

- Primary Erythromelalgia
- Inherited Erythromelalgia

## Interventions

- **DRUG:** XPF-002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01486446
- **Lead sponsor:** Xenon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-04
- **Final completion:** 2012-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01486446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01486446, "Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01486446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*